While gene and cell therapies (CGT) increasingly fill the drug pipeline, half of payers believe that the affordability of these treatments will be a major challenge in the next two to three years, according to a recent survey. And, as these innovative therapies are introduced to treat conditions that affect larger populations, the significance of […]